Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol
Open Access
- 15 January 2014
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 165 (1) , 126-133
Abstract
L‐asparaginase is an important drug in the treatment of childhood acute lymphoblastic leukaemia (ALL). Treatment is associated with several toxicities, including acute pancreatitis. Clinical course, presentation, re‐exposure to L‐asparginase after pancreatitis and risk of recurrent pancreatitis within an asparaginase‐intensive protocol has been poorly reported. Children (1–17 years) on the ongoing Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL2008 protocol with asparaginase‐associated pancreatitis (AAP) diagnosed between 2008 and 2012 were identified through the online NOPHO ALL toxicity registry. NOPHO ALL2008 includes eight or 15 doses of intramuscular pegylated L‐asparginase (PEG‐asparaginase) 1000 iu/m2/dose at 2–6 weeks intervals, with a total of 30 weeks of exposure to PEG‐asparaginase (clinicaltrials.gov no: NCT00819351). Of 786 children, 45 were diagnosed with AAP with a cumulative risk of AAP of 5·9%. AAP occurred after a median of five doses (range 1–13), and 11 d (median) from the latest administration of PEG‐Asparaginase. Thirteen patients developed pseudocysts (30%) and 11 patients developed necrosis (25%). One patient died from pancreatitis. Twelve AAP patients were re‐exposed to L‐asparginase, two of whom developed mild AAP once more, after four and six doses respectively. In conclusion, re‐exposure to PEG‐asparaginase in ALL patients with mild AAP seems safe.Keywords
This publication has 26 references indexed in Scilit:
- Complying with the European Clinical Trials directive while surviving the administrative pressure – An alternative approach to toxicity registration in a cancer trialEuropean Journal of Cancer, 2014
- Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensusGut, 2012
- Asparaginase revisitedLeukemia & Lymphoma, 2011
- Conservative treatment of L‐asparaginase‐associated lipid abnormalities in children with acute lymphoblastic leukemiaPediatric Blood & Cancer, 2010
- Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase‐associated pancreatitisPediatric Blood & Cancer, 2009
- L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemiaThrombosis and Haemostasis, 2008
- Predicting asparaginase‐associated pancreatitisPediatric Blood & Cancer, 2006
- Birth Weight and Risk for Childhood Leukemia in Denmark, Sweden, Norway, and IcelandJNCI: Journal of the National Cancer Institute, 2004
- A Clinically Based Classification System for Acute PancreatitisArchives of Surgery, 1993
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958